AlphAIAlphAI — Financial news for AI agents
investing.comOCT 192 min read$EVAX

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

Original reporting
investing.com
Published Oct 19, 2026, 4:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 4:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVAXBullishHigh
01

Why it matters

The three‑year follow‑up data confirms durable responses, likely attracting investors seeking biotech breakthroughs.

02

Market read

The trial results triggered a sharp stock rally and may influence peer biotech valuations.

03

What to watch

Small trial size and lack of regulatory approval timeline may limit upside.

Relevance 8/10Novelty 9/10Timing: today

Background

EVAX is a tech‑bio company developing AI‑guided personalized cancer vaccines.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

EVAX shares jumped 21.6% after the company announced positive three-year melanoma vaccine trial data.

Expected impact

upward pressure as market prices in the encouraging trial results

Evidence & confidence

The data shows maintained responses and no tumor progression, a material clinical milestone for a biotech.

Market effects

Sector

Boosts sentiment for the personalized cancer vaccine and broader biotech sector.

Regional

Positive for European biotech listings where similar platforms are based.

Global

Adds to the narrative of AI‑driven immunotherapy advances worldwide.

Counterpoint

What could challenge this read

If longer‑term efficacy or safety concerns emerge, the rally could be short‑lived.

Key entities

  • company
    Evaxion AS

    Developer of the EVX‑01 melanoma vaccine.

  • company
    Merck

    Partnered with EVAX in earlier trial phases.

Read at source← All news

StoryEvaxion reports three‑year durable responses with melanoma vaccine EVX‑01

Also covered by

1 outlet

Related articles

OCT 19
$EVAXMedAI 8/10

Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma

Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.

rttnews.com2 min
OCT 19
$EVAXMedAI 9/10

Evaxion reports three-year data for melanoma vaccine EVX-01

Evaxion A/S (EVAX) reported three-year data from its phase 2 trial of melanoma vaccine EVX-01, showing sustained clinical responses with no tumor progression. The data will be presented at the ESMO Congress 2026. Previously, two-year data showed a 75% objective response rate. EVX-01 is a personalized cancer vaccine currently being evaluated for advanced melanoma.

investing.com2 min
OCT 19
$EVAXHighAI 8/10

No tumor progression was seen at three-year follow-up in Evaxion's melanoma vaccine trial.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All patients showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 showed a 75% objective response rate, with 25% of patients achieving complete response.

stocktitan.net2 min
OCT 2
$EVAXMedAI 8/10

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.

globenewswire.com2 min